Abbott markets its MitraClip device for treating mitral valve regurgitation in the U.S. and won pre-market approval in October 2013. It is the first transcatheter mitral valve repair to hit the market. The company has since been acquiring other vascular companies in the industry and is taking steps to get its valves available globally.
The company recently won Japanese reimbursement nod for the MitraClip. Japan’s Ministry of Health and Welfare granted Abbott the reimbursement after approving the device in November last year.